
<DOC>
<DOCNO>
WSJ900516-0086
</DOCNO>
<DOCID>
900516-0086.
</DOCID>
<HL>
   Financing Business:
   Lidak Pharmaceuticals
</HL>
<DATE>
05/16/90
</DATE>
<SO>
WALL STREET JOURNAL (J), NO PAGE CITATION
</SO>
<CO>
   LDAKA
</CO>
<IN>
INITIAL STOCK OFFERINGS (INI)
STOCK MARKET, OFFERINGS (STK)
</IN>
<LP>
   LIDAK PHARMACEUTICALS said it completed its initial public
offering of one million units at $5 each. Each unit consists
of five common shares and five redeemable Class A warrants.
Each Class A warrant is exercisable to buy one common share
and one redeemable Class B warrant at $1.50 until May 8,
1995. Each Class B warrant holder may buy one common share at
$2.25 until May 8, 1995. D.H. Blair &amp; Co. managed the
underwriters, the La Jolla, Calif., company said. Proceeds
will be used to fund human clinical trials of a therapeutic
product to treat herpes and certain inflammatory skin
disorders and for research and development of other
pharmaceutical products.
</LP>
<TEXT>
</TEXT>
</DOC>